Moving from Manual Inspection to Machine Vision: A Regulatory Field Guide for Medical Device Quality Teams
Blog post from Roboflow
Following the February 2026 replacement of the FDA’s Quality System Regulation with the QMSR, which incorporates ISO 13485:2016 and expands FDA access to internal audit and management-review records, medical-device manufacturers are encouraged to strengthen documentation for production changes such as replacing manual inspection with automated computer vision. For many Class II devices, a machine-vision upgrade that does not alter the product’s design, materials, intended use, or indications generally does not require a new 510(k), but it requires a well-supported Letter to File demonstrating equivalent or improved defect detection and no new safety risks. The recommended evidence package includes a documented baseline of manual inspection performance, IQ/OQ/PQ process validation, risk-based software assurance, statistically justified method-comparison studies, acceptance-activity records in the device history record, updated risk-management and nonconformance procedures, controlled change documentation, and current training and supplier qualification records. The discussion also highlights common FDA inspection concerns, including inadequate process or software validation, missing change-control approvals, and unsupported sampling plans, while noting that 100% automated inspection may reduce reliance on sampling if appropriately validated.
No tracked trend matches for this post yet.
Use this post, company, and trend context to find content marketing opportunities, perform competitive analysis, or address product feature gaps via the Plushcap MCP server or the Plushcap API.